K. Kurkinen

CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe

P. Neuvonen, M. Niemi, J. Backman, 2009, Drug Metabolism and Disposition.

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

P. Neuvonen, M. Niemi, M. Fromm, 2009, Clinical pharmacology and therapeutics.

Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S‐ketamine

P. Neuvonen, K. Laine, K. Olkkola, 2010, European journal of pain.